Pyxis Oncology, Inc. (PYXS) shareholders
Close on Nov 17, 2026Market cap $120.11MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| GordonMD Long Biased Master Fund LP Joint filing with GordonMD Global Investments LP (17.50%), GordonMD Long Biased GP LLC (17.50%) and 1 more | 27,988,714 | 17.50% | 13G (passive) amendment | Oct 1, 2026 |
| GordonMD Global Investments LP Joint filing with GordonMD Long Biased Master Fund LP (16.40%), GordonMD Long Biased GP LLC (16.40%) and 1 more | 20,441,948 | 16.40% | 13G (passive) amendment | Oct 1, 2026 |
| GordonMD Long Biased GP LLC Joint filing with GordonMD Global Investments LP (12.10%), GordonMD Long Biased Master Fund LP (12.10%) and 1 more | 10,024,909 | 12.10% | 13G (passive) amendment | Jun 30, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 8,336,902 | 9.99% | 13G (passive) | Jul 2, 2026 |
| Lara Sullivan, M.D. | 7,543,007 | 11.21% | 13D (active) amendment | Mar 31, 2025 |
| Lara Sullivan | 6,624,699 | 10.30% | 13D (active) amendment | Dec 23, 2024 |
| Coastlands Capital LP Joint filing with Coastlands Capital Partners LP (5.42%), Coastlands Capital GP LLC (5.42%) and 2 more | 6,448,907 | 5.42% | 13G (passive) | Oct 1, 2026 |
| Benjamin Alexander Smith Joint filing with Laurion Capital Management LP (7.72%), Janaka Sheehan Maduraperuma (7.72%) | 4,796,479 | 7.72% | 13G (passive) amendment | Dec 31, 2025 |
| Janaka Sheehan Maduraperuma Joint filing with Laurion Capital Management LP (5.16%), Benjamin Alexander Smith (5.16%) | 4,300,888 | 5.16% | 13G (passive) amendment | Sep 30, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.70%), Israel A. Englander (5.70%) | 3,542,663 | 5.70% | 13G (passive) | Jun 27, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.30%), Israel A. Englander (5.30%) and 1 more | 3,160,139 | 5.30% | 13G (passive) | Dec 9, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PYXS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 10,024,909 | 12.02% | $30.17M | +5,903,039 | 14.60% |
| Pfizer Inc | 7,032,770 | 8.43% | $19.48M | – | 11.43% |
| Laurion Capital Management LP | 4,900,888 | 5.88% | $14.75M | −96,445 | 0.38% |
| Vanguard Capital Management LLC | 2,075,997 | 2.49% | $6.25M | +42,487 | 0.00% |
| HealthInvest Partners AB | 966,459 | 1.16% | $2.91M | +769,423 | 0.78% |
| BlackRock, Inc. | 867,934 | 1.04% | $2.61M | +79,095 | 0.00% |
| Palo Alto Investors LP | 864,277 | 1.04% | $2.60M | −146,233 | 0.36% |
| Marshall Wace, Llp | 830,544 | 1.00% | $2.50M | +476,127 | 0.00% |
| Renaissance Technologies LLC | 772,232 | 0.93% | $2.32M | −116,448 | 0.00% |
| Geode Capital Management, LLC | 591,849 | 0.71% | $1.78M | −6,272 | 0.00% |
| Woodline Partners LP | 523,999 | 0.63% | $1.58M | New | 0.00% |
| 683 Capital Management, LLC | 459,367 | 0.55% | $1.38M | −436,896 | 0.07% |
| Jacobs Levy Equity Management, Inc | 428,606 | 0.51% | $1.29M | −32,391 | 0.00% |
| Longaeva Partners L.P. | 353,582 | 0.42% | $1.06M | −149,632 | 0.02% |
| Decheng Capital LLC | 326,810 | 0.39% | $983.70K | – | 0.13% |
| Vanguard Fiduciary Trust Co | 302,986 | 0.36% | $911.99K | +2,089 | 0.00% |
| Jane Street Group, LLC | 290,090 | 0.35% | $873.17K | −14,369 | 0.00% |
| State Street Corp | 248,837 | 0.30% | $749.00K | – | 0.00% |
| Millennium Management LLC | 233,004 | 0.28% | $701.34K | −164,621 | 0.00% |
| UBS Group AG | 155,217 | 0.19% | $467.20K | −98,907 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 76 | 34M | 40.9% | 9 / 24 | 24 / 10 | 8M | 2M |
| Q1 2026 | 78 | 28M | 33.1% | 14 / 11 | 36 / 14 | 4M | 4M |
| Q4 2025 | 79 | 30M | 36.2% | 22 / 24 | 19 / 14 | 9M | 6M |
| Q3 2025 | 73 | 27M | 32.2% | 14 / 11 | 31 / 15 | 5M | 5M |
| Q2 2025 | 74 | 28M | 33.0% | 15 / 21 | 23 / 30 | 4M | 7M |
| Q1 2025 | 89 | 30M | 36.3% | 13 / 22 | 26 / 22 | 2M | 4M |
| Q4 2024 | 99 | 32M | 37.8% | 25 / 32 | 20 / 18 | 12M | 8M |
| Q3 2024 | 92 | 28M | 33.5% | 23 / 29 | 17 / 9 | 7M | 5M |
| Q2 2024 | 80 | 28M | 33.8% | 25 / 20 | 21 / 16 | 8M | 2M |
| Q1 2024 | 71 | 23M | 27.6% | 30 / 22 | 5 / 9 | 15M | 1M |
| Q4 2023 | 51 | 9M | 10.6% | 9 / 11 | 12 / 11 | 2M | 1M |
| Q3 2023 | 54 | 8M | 9.4% | 14 / 15 | 13 / 7 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
17 funds held PYXS in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PYXS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,422,296 | 1.71% | $4.28M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 558,775 | 0.67% | $1.68M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 374,680 | 0.45% | $1.13M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 271,545 | 0.33% | $488.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 166,564 | 0.20% | $501.36K | 0.03% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 90,276 | 0.11% | $162.50K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 78,709 | 0.09% | $141.68K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 70,060 | 0.08% | $210.88K | 0.14% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 38,072 | 0.05% | $68.53K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 26,866 | 0.03% | $80.87K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 26,650 | 0.03% | $80.22K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 11,188 | 0.01% | $33.68K | 0.02% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 10,263 | 0.01% | $27.20K | 0.00% | Jul 31, 2026 |
| Victory Extended Market Index Fund | 5,968 | 0.01% | $15.82K | 0.00% | Jul 31, 2026 |
| JNL/DFA U.S. Small Cap Fund | 3,922 | 0.00% | $11.81K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas Civik | CEO & Chairman of the Board, Director | 221,886 | 0.27% | Sep 8, 2026 |
| Lara Sullivan | President ,CEO & CMO, Director | 2,403,882 | 2.88% | Apr 2, 2025 |
| Jitendra Wadhane | Prin Fin & Acct Officer | 512,882 | 0.61% | Mar 25, 2026 |
| Pamela Ann Connealy | CFO & COO | 3,425,179 | 4.11% | Apr 2, 2025 |
| Rachel Humphrey | Director | 81,309 | 0.10% | Nov 6, 2026 |
| Jakob Dupont | Director | 73,741 | 0.09% | Aug 20, 2026 |
| Santhosh Palani | Director | 6,000 | 0.01% | Mar 25, 2026 |
| Michael A. Metzger | Director | – | – | Mar 25, 2026 |
| Freda C. Lewis-Hall | Director | 241,405 | 0.29% | Mar 25, 2026 |
| John L. Flavin | Director | 413,015 | 0.50% | Mar 25, 2026 |
| Darren S. Cline | Director | 251,405 | 0.30% | Mar 25, 2026 |
| Long Biased Master Fund LP GordonMD | 10% owner | – | – | Oct 9, 2026 |
| Long Biased GP LLC GordonMD | 10% owner | 10,024,909 | 12.02% | Oct 9, 2026 |
| Craig D. Gordon | 10% owner | – | – | Oct 9, 2026 |
| Global Investments LP GordonMD | 10% owner | 15,541,909 | 18.63% | Oct 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Global Investments LP GordonMD 10% owner | Oct 1, 2026 | Buy | +5,517,000 | – | – | 15,541,909 |
| Jakob Dupont Director | Jun 30, 2026 | Option exercise | +35,000 | $1.60 | $56.00K | 73,741 |
| Jakob Dupont Director | Jun 30, 2026 | Sale(10b5-1 plan) | −35,000 | $3.06 | $107.10K | 38,741 |
| Jitendra Wadhane Prin Fin & Acct Officer | Mar 24, 2026 | Award | +109,461 | – | – | 512,882 |
| Rachel Humphrey Director | Apr 21, 2025 | Sale(10b5-1 plan) | −13,896 | $1.03 | $14.31K | 81,309 |
| Rachel Humphrey Director | Apr 17, 2025 | Sale(10b5-1 plan) | −200 | $0.97 | $194 | 95,205 |
| Rachel Humphrey Director | Apr 14, 2025 | Sale(10b5-1 plan) | −1,400 | $0.97 | $1.36K | 95,405 |
| Pamela Ann Connealy CFO & COO | Nov 26, 2024 | Buy | +83,400 | $1.96 | $163.46K | 1,199,143 |
| Pamela Ann Connealy CFO & COO | Nov 26, 2024 | Buy | +5,450 | $2.00 | $10.90K | 1,115,743 |
| Santhosh Palani Director | Jun 7, 2024 | Award | +6,000 | – | – | 6,000 |
| Freda C. Lewis-Hall Director | Mar 26, 2024 | Award | +35,219 | – | – | 241,405 |
| Jitendra Wadhane SVP, Chief Accounting Officer | Mar 26, 2024 | Award | +131,484 | – | – | 398,421 |
| Rachel Humphrey Director | Mar 26, 2024 | Award | +38,741 | – | – | 96,805 |
| John L. Flavin Director | Mar 26, 2024 | Award | +35,219 | – | – | 413,015 |
| Jakob Dupont Director | Mar 26, 2024 | Award | +38,741 | – | – | 38,741 |
| Pamela Ann Connealy CFO & COO | Mar 26, 2024 | Award | +328,710 | – | – | 1,110,293 |
| Darren S. Cline Director | Mar 26, 2024 | Award | +35,219 | – | – | 251,405 |
| Pamela Ann Connealy CFO and COO | Nov 29, 2023 | Tax withholding | −36,949 | $1.40 | $51.73K | 781,583 |
| Jitendra Wadhane Chief Accounting Officer | Nov 15, 2023 | Award | +40,000 | – | – | 266,937 |
| Pamela Ann Connealy CFO and COO | Sep 28, 2023 | Buy | +8,000 | $1.87 | $14.96K | 818,532 |
| Pamela Ann Connealy CFO and COO | Sep 27, 2023 | Buy | +6,426 | $1.85 | $11.89K | 810,532 |
| Jitendra Wadhane Chief Accounting Officer | Sep 27, 2023 | Buy | +2,500 | $1.87 | $4.68K | 226,937 |
| Pamela Ann Connealy CFO and COO | Sep 25, 2023 | Buy | +12,000 | $1.67 | $20.04K | 804,106 |
| Jitendra Wadhane Chief Accounting Officer | Sep 25, 2023 | Buy | +5,000 | $1.77 | $8.85K | 224,437 |
| Jitendra Wadhane Chief Accounting Officer | Sep 22, 2023 | Buy | +2,500 | $1.74 | $4.35K | 219,437 |
| Pamela Ann Connealy CFO and COO | Sep 22, 2023 | Buy | +5,000 | $1.74 | $8.70K | 792,106 |
| Lara Sullivan President and CEO, Director | Sep 18, 2023 | Sale | −8,541 | $2.10 | $17.94K | 2,403,882 |
| Lara Sullivan President and CEO, Director | Sep 14, 2023 | Sale | −100 | $2.25 | $225 | 2,412,423 |
| Lara Sullivan President and CEO, Director | Sep 13, 2023 | Tax withholding | −184,742 | $2.13 | $393.50K | 2,412,523 |
| Lara Sullivan President and CEO, Director | Sep 13, 2023 | Sale | −3,000 | $2.27 | $6.81K | 2,597,265 |
| Lara Sullivan President and CEO, Director | Sep 12, 2023 | Sale | −4,917 | $2.25 | $11.06K | 2,600,265 |
| Lara Sullivan President and CEO, Director | Sep 11, 2023 | Sale | −20,000 | $2.27 | $45.40K | 2,605,182 |
| Pamela Ann Connealy CFO and COO | Sep 7, 2023 | Award | +187,793 | – | – | 782,106 |
| Jitendra Wadhane Chief Accounting Officer | Sep 7, 2023 | Award | +93,896 | – | – | 211,937 |
| Lara Sullivan President and CEO, Director | Sep 7, 2023 | Award | +469,483 | – | – | 2,625,182 |
| Jay Feingold Chief Medical Officer | Mar 24, 2023 | Award | +209,803 | – | – | 730,345 |
| Lara Sullivan President and CEO, Director | Mar 24, 2023 | Award | +703,379 | – | – | 2,155,699 |
| Pamela Ann Connealy CFO and COO | Mar 24, 2023 | Award | +209,803 | – | – | 594,313 |
| John L. Flavin Director | Mar 24, 2023 | Award | +139,355 | – | – | 377,796 |
| Freda C. Lewis-Hall Director | Mar 24, 2023 | Award | +139,355 | – | – | 206,186 |
| Rachel Humphrey Director | Mar 24, 2023 | Award | +58,064 | – | – | 58,064 |
| Darren S. Cline Director | Mar 24, 2023 | Award | +139,355 | – | – | 216,186 |
| Jitendra Wadhane Chief Accounting Officer | Mar 24, 2023 | Award | +45,000 | – | – | 88,648 |
| Jitendra Wadhane Chief Accounting Officer | Mar 24, 2023 | Award | +29,393 | – | – | 118,041 |
| Thomas Civik Director | Mar 24, 2023 | Award | +139,355 | – | – | 206,186 |
| Inc Pfizer 10% owner | Mar 17, 2023 | Buy | +1,811,594 | $2.76 | $5.00M | 5,952,263 |
| Inc Pfizer 10% owner | Mar 17, 2023 | Buy | +1,811,594 | $2.76 | $5.00M | 5,952,263 |
| Jay Feingold Chief Medical Officer | Jan 3, 2023 | Award | +53,931 | – | – | 520,542 |
| Pamela Ann Connealy Chief Financial Officer | Jan 3, 2023 | Award | +43,493 | – | – | 384,510 |
| Lara Sullivan Chief Executive Officer, Director | Jan 3, 2023 | Award | +95,684 | – | – | 1,452,320 |
| Mark Chin – | Apr 21, 2022 | Sale | −1,745,761 | $3.05 | $5.32M | 0 |
| Jay Feingold Chief Medical Officer | Apr 14, 2022 | Award | +115,931 | – | – | 466,611 |
| Lara Sullivan Chief Executive Officer, Director | Apr 14, 2022 | Award | +315,273 | – | – | 1,356,636 |
| Pamela Ann Connealy Chief Financial Officer | Apr 14, 2022 | Award | +93,493 | – | – | 341,017 |
| Darren S. Cline Director | Mar 31, 2022 | Award | +66,831 | – | – | 76,831 |
| Jay Feingold Chief Medical Officer | Mar 31, 2022 | Award | +306,930 | – | – | 350,680 |
| Thomas Civik Director | Mar 31, 2022 | Award | +66,831 | – | – | 66,831 |
| Pamela Ann Connealy Chief Financial Officer | Mar 31, 2022 | Award | +247,524 | – | – | 247,524 |
| John L. Flavin Director | Mar 31, 2022 | Award | +66,831 | – | – | 238,441 |
| Freda C. Lewis-Hall Director | Mar 31, 2022 | Award | +66,831 | – | – | 66,831 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pyxis Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 46,846 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jakob Dupont Director | Jun 30, 2026 | 35,000 | $107.03K | Jun 30, 2026 | Stock Option Exercise |
| Rachel Humphrey Director | Apr 21, 2025 | 13,896 | $14.36K | Apr 21, 2025 | Restricted Stock Vesting |
| Rachel Humphrey Director | Apr 17, 2025 | 200 | $194 | Apr 17, 2025 | Restricted Stock Vesting |
| Rachel Humphrey Director | Apr 14, 2025 | 1,400 | $1.36K | Apr 14, 2025 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 18, 2023 | 8,541 | $17.94K | Sep 18, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 14, 2023 | 100 | $225 | Sep 14, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 13, 2023 | 3,000 | $6.82K | Sep 13, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 12, 2023 | 4,917 | $11.07K | Sep 12, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 11, 2023 | 20,000 | $45.41K | Sep 11, 2023 | Restricted Stock Vesting |
| Feingold Jay Former Chief Medical Officer | Sep 5, 2023 | 18,109 | $42.92K | Sep 5, 2023 | Option Granted - 08/16/2021 |
| Feingold Jay Former Chief Medical Officer | Aug 11, 2023 | 50,000 | $126.48K | Aug 11, 2023 | Restricted Stock Vesting |
| Feingold Jay Former Chief Medical Officer | Aug 1, 2023 | 25,000 | $63.07K | Aug 1, 2023 | Restricted Stock Vesting |
| Feingold Jay Former Chief Medical Officer | Jul 31, 2023 | 25,000 | $64.60K | Jul 31, 2023 | Restricted Stock Vesting |
| Feingold Jay Former Chief Medical Officer | Jul 28, 2023 | 23,021 | $56.01K | Jul 27, 2023 | Restricted Stock Vesting |
| Feingold Jay Former Chief Medical Officer | Jul 27, 2023 | 23,021 | $56.01K | Jul 27, 2023 | Restricted Stock Vesting |
See a number that looks wrong?